2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.
Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin-eligibility status.
Checkpoint inhibitors pembrolizumab (Keytruda) and atezolizumab (Tecentriq), as single agents, have demonstrated activity in the neoadjuvant setting with pathologic complete response (pCR) rates of 30% to 40%.
For cisplatin-eligible patients, phase III trials are underway exploring these agents in combination with platinum-based chemotherapy. Pembrolizumab in combination with gemcitabine, for example, reported a pCR rate of approximately 45%, says Sonpavde.
Conversely, immunotherapy alone is being explored for cisplatin-ineligible patients compared with standard cystectomy, says Sonpavde.